Glenmark gets nod for marketing two drugs in US
30 May 2008
Mumbai: Glenmark Pharmaceuticals has received FDA approval to market drugs that treat skin disorders and diabetes in the US.
The approval covers Mometasone Furoate ointment and cream, used to treat inflammatory skin disorders, and Metformin hydrochloride tables, used for lowering blood sugar levels, Glenmark said in a filing with the Bombay Stock Exchange.
Glenmrk's US subsidiary Glenmark Generics Ltd (GGL) received ANDA approval for its anti-inflammatory and anti-diabetic drugs and will soon commence marketing and distribution of these products in the US market, the company said.
GGL will soon start marketing Mometasone Furoate Ointment, Mometasone Furoate Cream and Metformin Hydrochloride tablets in the US market, the company said in the filing.
The two Mometasone Furoate products had sales of over $29 million in the 12-month period ended 31 March 2008 while Metform in Hydrochloride had total sales of over $158 million for the year, as per IMS Health.
Mometasone would be manufactured at Glenmark's USFDA approved Baddi unit in Himachal Pradesh.
GGL also holds US manufacturing rights for a line of Chobetasol Propionate dermatology products which it acquired through a US-based pharmaceutical development company.
GGL now has a portfolio of 32 generic products for the US market and over 35 ANDAs awaiting US FDA approval.
.webp)
.webp)
